Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lesinurad/Allopurinol FDC vs Coadministration in Fed Healthy Adults
NCT02888054Phase 1Completed
- Sponsor
- Ardea Biosciences, Inc.
- Start
- Aug 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lesinurad and allopurinol in gout and hyperuricemia (4 arms), sponsored by Ardea Biosciences, Inc. Primary endpoints: Maximum Observed Concentration at Day 22, Time of Maximum Observed Concentration at Day 22 and 3 more. Started Aug 2016; status: completed.
02
Drugs
lesinuradallopurinol
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02888054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888054.